We are live on ! Find out more
MREO

Mereo BioPharma
MREO

61 hedge funds and large institutions have $46.2M invested in Mereo BioPharma in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 14

7% more call options, than puts

Call options by funds: $93K | Put options by funds: $87K

1.03% less ownership

Funds ownership: 10.88% → 9.85% (-1%)

3% less funds holding

Funds holding: 63 → 61 (-2)

7% less capital invested

Capital invested by funds: $49.4M → $46.2M (-$3.27M)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
61
Holders Change
-2
Holders Change %
-3.17%
% of All Funds
0.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
15
Reduced
14
Closed
8
Calls
$93K
Puts
$87K
Net Calls
+$6K
Net Calls Change
+$55K

Top Buyers

Rank Fund Capital Flow
1
MAM
Monaco Asset Management
Monaco
+$1.53M
2
Goldman Sachs
Goldman Sachs
New York
+$1.3M
3
E
Ergoteles
New York
+$109K
4
JP Morgan Chase
JP Morgan Chase
New York
+$109K
5
Barclays
Barclays
United Kingdom
+$104K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.46M
2
CC
Clearline Capital
New York
-$1.56M
3
BlackRock
BlackRock
New York
-$565K
4
Morgan Stanley
Morgan Stanley
New York
-$99.9K
5
CHAM
Clear Harbor Asset Management
Connecticut
-$50.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$7.95M – – –
RCMNY
2
Rubric Capital Management (New York)
New York
$7.77M – – –
SCM
3
Suvretta Capital Management
New York
$5.52M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$4.68M – – –
Citadel Advisors
5
Citadel Advisors
Florida
$2.3M -$11.1K -13,555 -0.4%
Goldman Sachs
6
Goldman Sachs
New York
$1.72M +$1.3M +1,585,640 +224%
BC
7
Boxer Capital
California
$1.69M – – –
TC
8
Tejara Capital
United Kingdom
$1.64M +$1.8M +2,188,606 New
Alkeon Capital Management
9
Alkeon Capital Management
New York
$1.6M – – –
CC
10
Clearline Capital
New York
$1.54M -$1.56M -1,904,426 -48%
MAM
11
Monaco Asset Management
Monaco
$1.54M +$1.53M +1,863,005 +998%
TCM
12
Tekla Capital Management
Massachusetts
$1.16M – – –
AG
13
Artal Group
Luxembourg
$1.13M – – –
Millennium Management
14
Millennium Management
New York
$984K +$47.4K +57,738 +5%
Renaissance Technologies
15
Renaissance Technologies
New York
$943K +$19.5K +23,755 +2%
DCM
16
DAFNA Capital Management
California
$822K – – –
OCA
17
Octagon Capital Advisors
New York
$750K – – –
TI
18
Tidal Investments
Wisconsin
$235K +$25.7K +31,310 +11%
JGC
19
J. Goldman & Co
New York
$233K – – –
Primecap Management
20
Primecap Management
California
$223K -$14.4K -17,530 -6%
FAM
21
Formidable Asset Management
Ohio
$216K +$5.14K +6,262 +2%
Jane Street
22
Jane Street
New York
$145K +$15.7K +19,176 +11%
PFMU
23
Privium Fund Management (UK)
United Kingdom
$133K – – –
Barclays
24
Barclays
United Kingdom
$125K +$104K +127,171 +322%
SSA
25
Schonfeld Strategic Advisors
New York
$117K +$3.78K +4,600 +3%
1
2 3

MREO Hedge Fund Activity: Q4 2022 in Review

61 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2022, worth a combined $46.2M — down 6.6% from $49.4M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of MREO and 6 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 15 added.

The largest buyer was Monaco Asset Management, adding an estimated $1.53M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $8.46M sold.

  • 61 institutional investors held Mereo BioPharma (MREO) as of Q4 2022, down from 63 in Q3 2022.
  • Funds reported $46.2M of Mereo BioPharma stock for Q4 2022, down 6.6% quarter-over-quarter.
  • 6 funds opened new Mereo BioPharma positions in Q4 2022 and 8 closed out, a net change of -2 holders.
  • The largest Mereo BioPharma buyer in Q4 2022 was Monaco Asset Management, an estimated $1.53M added.
  • The largest Mereo BioPharma seller in Q4 2022 was Point72 Asset Management, an estimated $8.46M sold.

Based on aggregated 13F filings for Q4 2022.